D7Ertd443e is an alias for FATS (fragile site-associated tumor suppressor). FATS, an (E2-independent) E3 ubiquitin-conjugating enzyme, is involved in tumor-related processes. It may be associated with pathways regulating the immune response in the context of cancer, with its function having potential implications for understanding tumor development and immunity [1].

Fats-/-mice (KO mouse model) show reduced subcutaneous B16 melanoma and H7 pancreatic tumor growth compared to WT controls. This reduced growth is macrophage-dependent and linked to a shift of macrophages within the tumor from tumor-promoting M2-like to antitumor M1-like macrophages. FATS deficiency promotes M1 polarization by disrupting NF-κB/IκBα negative feedback loops, stimulating and prolonging NF-κB activation. It also indirectly enhances CD4+ T helper type 1 (Th1) and cytotoxic T lymphocyte (CTL) adaptive immune responses to promote tumor regression [1].

In conclusion, FATS (D7Ertd443e) functions as an immune regulator in tumor development. The Fats-/-mouse model has revealed its role in promoting antitumor immunity, suggesting its potential as a target in cancer immunotherapy.